S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
30 Days of MarketBeat All Access Free (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
30 Days of MarketBeat All Access Free (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
30 Days of MarketBeat All Access Free (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
30 Days of MarketBeat All Access Free (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
NASDAQ:VCYT

Veracyte (VCYT) Stock Forecast, Price & News

$22.47
-0.13 (-0.58%)
(As of 09/22/2023 ET)
Compare
Today's Range
$22.21
$22.98
50-Day Range
$22.47
$29.92
52-Week Range
$14.92
$32.40
Volume
439,060 shs
Average Volume
482,328 shs
Market Capitalization
$1.63 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.60

Veracyte MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
36.2% Upside
$30.60 Price Target
Short Interest
Healthy
3.49% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.03
Upright™ Environmental Score
News Sentiment
0.79mentions of Veracyte in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$305,000 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.52) to ($0.31) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

347th out of 963 stocks

Medical Laboratories Industry

8th out of 23 stocks


VCYT stock logo

About Veracyte (NASDAQ:VCYT) Stock

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

VCYT Price History

VCYT Stock News Headlines

Veracyte Inc (VCYT)
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Here's Why This Little-Known Growth Stock Is a Buy
See More Headlines
Receive VCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter.

VCYT Company Calendar

Last Earnings
8/08/2023
Today
9/24/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VCYT
Employees
787
Year Founded
2006

Price Target and Rating

Average Stock Price Forecast
$30.60
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$23.00
Forecasted Upside/Downside
+36.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$-36,560,000.00
Pretax Margin
-8.73%

Debt

Sales & Book Value

Annual Sales
$296.54 million
Book Value
$14.98 per share

Miscellaneous

Free Float
70,859,000
Market Cap
$1.63 billion
Optionable
Optionable
Beta
1.32

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Marc A. StapleyMr. Marc A. Stapley (Age 53)
    CEO & Director
    Comp: $1.25M
  • Ms. Rebecca  ChambersMs. Rebecca Chambers (Age 45)
    Exec. VP & CFO
    Comp: $772.41k
  • Ms. Annie McGuire (Age 42)
    Exec. VP, Gen. Counsel & Chief People Officer
    Comp: $633.65k
  • Mr. Jonathan Wygant (Age 52)
    VP & Chief Accounting Officer
  • Mr. Steven French
    Sr. VP & Chief Information Officer
  • Ms. Tracy Morris
    VP of Global Corp. Communications
  • Mr. Robert Brainin (Age 51)
    Exec. VP & Chief Bus. Officer
  • Dr. Fabienne Hermitte Ph.D.
    Sr. VP of Global Quality & Regulatory Affairs
  • Dr. John Leite Ph.D.
    Chief Commercial Officer for CLIA Bus.
  • Ms. Corinne Danan
    Sr. VP and GM of Biopharma & IVD Services













VCYT Stock - Frequently Asked Questions

Should I buy or sell Veracyte stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last twelve months. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VCYT shares.
View VCYT analyst ratings
or view top-rated stocks.

What is Veracyte's stock price forecast for 2023?

6 brokers have issued 1-year price targets for Veracyte's stock. Their VCYT share price forecasts range from $23.00 to $35.00. On average, they predict the company's stock price to reach $30.60 in the next year. This suggests a possible upside of 36.2% from the stock's current price.
View analysts price targets for VCYT
or view top-rated stocks among Wall Street analysts.

How have VCYT shares performed in 2023?

Veracyte's stock was trading at $23.73 on January 1st, 2023. Since then, VCYT stock has decreased by 5.3% and is now trading at $22.47.
View the best growth stocks for 2023 here
.

When is Veracyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our VCYT earnings forecast
.

How were Veracyte's earnings last quarter?

Veracyte, Inc. (NASDAQ:VCYT) announced its quarterly earnings results on Tuesday, August, 8th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.04. The biotechnology company earned $90.32 million during the quarter, compared to analysts' expectations of $83.05 million. Veracyte had a negative trailing twelve-month return on equity of 2.71% and a negative net margin of 8.84%. Veracyte's revenue for the quarter was up 24.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.13) earnings per share.

What guidance has Veracyte issued on next quarter's earnings?

Veracyte issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $342.00 million-$350.00 million, compared to the consensus revenue estimate of $335.77 million.

What other stocks do shareholders of Veracyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), CA (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).

What is Veracyte's stock symbol?

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Who are Veracyte's major shareholders?

Veracyte's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bank Julius Baer & Co. Ltd Zurich (48.69%), ARK Investment Management LLC (10.81%), BlackRock Inc. (9.50%), State Street Corp (4.97%), Artisan Partners Limited Partnership (4.89%) and Sumitomo Mitsui Trust Holdings Inc. (4.49%). Insiders that own company stock include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, Giulia C Kennedy, Jens Holstein, John L Bishop, John Walter Hanna Jr, Karin Eastham, Kevin K Gordon, Marc Stapley, Mark Ho and Muna Bhanji.
View institutional ownership trends
.

How do I buy shares of Veracyte?

Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Veracyte's stock price today?

One share of VCYT stock can currently be purchased for approximately $22.47.

How much money does Veracyte make?

Veracyte (NASDAQ:VCYT) has a market capitalization of $1.63 billion and generates $328.63 million in revenue each year. The biotechnology company earns $-36,560,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis.

How many employees does Veracyte have?

The company employs 787 workers across the globe.

Does Veracyte have any subsidiaries?
The following companies are subsidiares of Veracyte: Allegro Diagnostics, Decipher Biosciences Inc., Decipher Corp., Delight Merger Sub II LLC, HalioDx Inc., Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS.
Read More
How can I contact Veracyte?

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.veracyte.com. The biotechnology company can be reached via phone at (650) 243-6300, via email at keith@veracyte.com, or via fax at 650-243-6301.

This page (NASDAQ:VCYT) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -